MMTZF Stock Chart & Stats
$0.31
>-$0.01(-0.89%)
At close: 4:00 PM EDT
$0.31
>-$0.01(-0.89%)
Day’s Range― - ―
52-Week Range$0.16 - $4.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.53K
Market Cap
$34.86M
Enterprise Value$16.26
Total Cash (Recent Filing)$12.50M
Total Debt (Recent Filing)$1.90M
Price to Earnings (P/E)―
Beta0.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding181,497,670
10 Day Avg. Volume4,412
30 Day Avg. Volume3,527
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.44
Price to Sales (P/S)6.27
P/FCF Ratio-17.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.
Very Low Financial LeverageExtremely low leverage and a strong equity ratio reduce solvency risk and preserve strategic optionality through clinical cycles. This structural balance-sheet strength supports access to capital, strategic partnerships, and cushioning against development setbacks without urgent refinancing pressure.
Diversified Revenue/funding ModelA business model that includes licensing, milestone payments, royalties, and grants distributes commercial risk and provides non-dilutive funding pathways. Structurally, this reduces dependency on product sales timing and enables capital-efficient advancement of the pipeline through partnerships and staged payments.
Bears Say
Persistent Negative ProfitabilityOngoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.
Negative Free Cash FlowNegative free cash flow limits the firm's ability to internally fund trials and commercialization costs, forcing reliance on equity or partnership financing. While improvement is positive, durable operational health requires consistent positive FCF to reduce dilution risk and finance long-term growth.
Unprofitable With No Dividend SupportBeing unprofitable removes earnings-derived resilience and eliminates dividend income as investor support. Structurally this heightens dependence on capital markets and strategic deals for runway, increasing dilution and execution risk if clinical or commercialization milestones slip.
MindMaze Therapeutics Holding SA News
MMTZF FAQ
What was MindMaze Therapeutics Holding SA’s price range in the past 12 months?
MindMaze Therapeutics Holding SA lowest stock price was $0.16 and its highest was $4.88 in the past 12 months.
What is MindMaze Therapeutics Holding SA’s market cap?
MindMaze Therapeutics Holding SA’s market cap is $34.86M.
When is MindMaze Therapeutics Holding SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MindMaze Therapeutics Holding SA’s earnings last quarter?
Currently, no data Available
Is MindMaze Therapeutics Holding SA overvalued?
According to Wall Street analysts MindMaze Therapeutics Holding SA’s price is currently Overvalued.
Does MindMaze Therapeutics Holding SA pay dividends?
MindMaze Therapeutics Holding SA does not currently pay dividends.
What is MindMaze Therapeutics Holding SA’s EPS estimate?
MindMaze Therapeutics Holding SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MindMaze Therapeutics Holding SA have?
MindMaze Therapeutics Holding SA has 181,497,670 shares outstanding.
What happened to MindMaze Therapeutics Holding SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MindMaze Therapeutics Holding SA?
Currently, no hedge funds are holding shares in MMTZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MindMaze Therapeutics Holding SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics’ neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson’s therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―